Navigation Links
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
Date:10/17/2007

DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for poster presentations at the AACR-NCI-EORTC International Conference from Oct. 22-26 at the Moscone Center in San Francisco.

The poster presentations will focus on data concerning many of SuperGen's current oncology programs including the lead clinical compound, MP470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.

In addition to the poster presentations listed below, data on SuperGen's hypomethylating agent, S110, will be presented by Dr. Peter A. Jones on Wednesday, Oct. 24 at 8:00 a.m. in Plenary Session 3: Epigenetic Targets.

SuperGen's schedule of presentations is as follows:

Poster

Date Time (PDT) Abstract # and Title Number/Session

Tuesday, 12:30 p.m.- # 1026 - MP470 #A173

Oct. 23 2:30 p.m. suppresses repair of

double-strand breaks Poster Session A

5:30 p.m.- following treatment

7:30 p.m. with DNA-damaging

agents

Wednesday, 12:30 p.m.- # 1038 - The #B140

Oct. 24 2:30 p.m. decitabine-derived

demethylating Poster Session B

5:30 p.m.- dinucleotide, S110

7:30 p.m. shows improved

activity due to

increased drug

delivery and

stability

Thursday, 12:30 p.m.- # 907 - Effect of #C200

Oct. 25 2:30 p.m. small molecule

inhibitors of JAK2 Poster Session C

5:30 p.m.- kinase on modulating

7:30 p.m. signaling cascades

downstream of

cytokine receptors

Thursday, 12:30 p.m.- # 985 - A small #C208

Oct. 25 2:30 p.m. molecule inhibitor of

Pim-1 kinase with Poster Session C

5:30 p.m.- activity in both

7:30 p.m. hematological and

solid tumor

malignancies

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail: mary.vegh@supergen.com

E-mail: tenns@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chennai AIDS Campaign Highlights The Social Neglect Faced By Victims
2. Benzene Slick In China Highlights Water Pollution
3. India To Highlight Its Scientific Achievements
4. Homecare Association Highlights Cost-Effectiveness of Medicare and Medicaid
5. India To Highlight The Potential Role Of Ayurveda In London
6. Study Highlights Appetite Regulation Pathway, New Hope for Weight Loss
7. Study Highlights How Bacteria Respond To Changes In Environment
8. Drug Action Week to Highlight Effects of Alcohol
9. Clinton, Gates Highlight Treatment, Discrimination of AIDS
10. Highlights from World Transplant Congress
11. Latest IPCC Report Highlights Need for Integrated Climate/human Behavior Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... Only two months after the official release of The Private Collection ... XO Private has initiated a second print-run of its lavish luxury travel coffee table ... when open, weighs in at more than six kilos, retails at EUR 1,000 per ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology: